All In MedTech

Device Trial Radar · NCT06668935

Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

800

Planned (sponsor's estimate)

Start

Oct 24, 2024

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Abbott Diabetes CarePublic (ABT)
Sponsor type
Industry
First posted
Nov 1, 2024

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to see if the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) will help prolong the length of time people with diabetes maintain adherence to glucagon-like peptide 1 (GLP-1/GIP) agonists.

Conditions

  • Diabetes Mellitus

Interventions

  • To utilize the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) to help prolong the length of time people with diabetes maintain adherence to GLP-1 and dual GIP/GLP-1 agonistsDevice

    All subjects will then begin use of their prescribed GLP-1 or combination GIP/GLP-1 medication in accordance with the HCP's instructions. Subjects will be titrated to their maximum tolerable dose per the medication's approved titration schedule and according to their HCP's standard of care between Visits 2 and 3.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the length of time subjects in each group remain on a GLP-1 or GLP-1/GIP combination drugTime frame: 210 days

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Helios Clinical Research

    Paradise Valley, Arizona · Recruiting

  • East Coast Institute for Research, LLC

    Jacksonville, Florida · Recruiting

  • Excellence Medical and Research

    Miami Gardens, Florida · Recruiting

5 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.